Cyclin D1 and p16 in Recurrent Nasopharyngeal Carcinoma
Author Information
Author(s): Lin Ho-Sheng, Berry Gerald J, Sun Zijie, Fee Willard E Jr
Primary Institution: Stanford University Medical Center
Hypothesis
The study aims to examine the expression level of cyclin D1 and p16 in recurrent nasopharyngeal carcinoma that have failed previous treatment.
Conclusion
The study found that while cyclin D1 expression in recurrent NPC was similar to untreated cancers, p16 expression was significantly lower, suggesting a potential survival advantage for cancer cells lacking p16.
Supporting Evidence
- Cyclin D1 was positively expressed in 26% of recurrent NPC specimens.
- Only 4% of recurrent NPC specimens showed positive p16 expression.
- The study suggests that loss of p16 may confer a survival advantage to cancer cells.
- Asian patients had a significantly better 5-year disease-free survival compared to non-Asian patients.
Takeaway
This study looked at how two proteins, cyclin D1 and p16, behave in patients with nasopharyngeal cancer that came back after treatment. They found that most of these cancers didn't have p16, which might help them survive treatment better.
Methodology
The study involved immunohistochemical analysis of 27 pathologic specimens from patients who underwent salvage nasopharyngectomy.
Potential Biases
The lack of pre-treatment specimens raises questions about whether the loss of p16 was pre-existing or a result of treatment.
Limitations
The study had a small sample size and lacked pre-irradiated NPC specimens for comparison.
Participant Demographics
The average age was 51 years, with 18 men and 9 women; 13 were Asian and 14 were non-Asians.
Statistical Information
P-Value
0.003
Statistical Significance
p = 0.003
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website